Gene-Silencing Pesticides Pose New Risks to Health, Environment and Farmers
By Eva Sirinathsinghji, Kendra Klein and Dana Perls,
Friends of the Earth
| 10. 06. 2020
WASHINGTON — “Gene-silencing pesticides” now under development pose unique risks to surrounding ecosystems and beneficial insects, including bees, according to a new report, released today by Friends of the Earth and Dr. Eva Sirinathsinghji. The report summarizes the gaps in research on experimental gene-silencing pesticides and the risks they pose to human health, the environment, and farmers.
Several biotech and agrichemical companies are moving quickly to patent and bring gene-silencing pesticides to market. Corporations including Bayer [OTCMKTS: BAYRY], BASF [OTCMKTS: BASFY], and Syngenta [owned by Sinochem-ChemChina], are using genetic engineering to develop the new pesticide sprays that exploit a cellular process called RNA interference (RNAi), in order to switch off or “silence” genes that are essential for the survival of insects — thus killing them.
The first gene-silencing pesticide spray is slated to be submitted to the U.S. EPA for registration by the end of this year. The product, developed by GreenLight Biosciences, targets the Colorado potato beetle. The spray is designed to be applied to crop leaves. When a beetle eats the contaminated leaves, genetic material enters the...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...